Deal Coming To A Close On 'Green Whistle' Inhaler For Pain Relief
the Clinical Pain Advisor take:
Officials with Medical Developments International Limited announced they have agreed to a term sheet and will now move to contract with a pharmaceutical company having expertise in pain management products.
The agreement would enable Medical Developments to distribute Penthrox within the 28 member states of the European Union, except for the United Kingdom, Ireland, and Hungary where MDI has existing distribution agreements, and within other European countries.
The potential transaction calls for upfront and milestone payments of $54.5 million including:
- $7.0 million upon signing.
- $3.0 million upon receiving Marketing Authorisation approvals in France (expected very shortly) and Belgium (already received).
- $7.0 million upon receiving reimbursement in Germany, Italy, Spain and France.
- The remaining $37.5 million relates to sales milestones potentially earned more than the term of the deal.
Additionally, MVP will receive a gross margin on product sold to partner and royalties based on net sales.
According to materials on Medical Development International's website, this medication is indicated for the relief of pain by "self administration in conscious hemodynamically stable patients with trauma and associated pain."
It is also indicated "for the relief of pain in monitored conscious patients who require analgesia for surgical procedures such as the change of dressings."
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Methadone Improves Short-Term Outcomes Better Than Morphine in Neonatal Abstinence Syndrome
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Hospital-Owned Practices Associated With Positive Workplace Perceptions Among Staff
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Chinese Traditional Medicine Showed Effectiveness on Pain, Quality of Life in Advanced Cancer